

Nomenclature of quantities and units in thrombosis and haemostasis (Recommendation 1993)

Citation for published version (APA):

Blomback, M., Abildgaard, U., van den Besselaar, A. M. H. P., Clementson, K. J., Dahlbäck, B., Exner, T., Francis, C. W., Gaffney, P., Gralnick, H., Hoyer, L. W., Johnson, G. J., Kasper, C., Lane, D., Lijnen, H. R., Lusher, J. M., Mannucci, P. M., Poller, L., Rapaport, S. I., Saito, H., ... Thorsen, S. (1994). Nomenclature of quantities and units in thrombosis and haemostasis (Recommendation 1993): A collaborative project of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC)). *Thrombosis and Haemostasis*, 71(3), 375-394.

Document status and date:

Published: 01/01/1994

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 05 May. 2023

Scientific and Standardization Committee Communications

Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993)

A Collaborative Project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC))

Chairman of the SSC Nomenclature Project and Past-Chairman of the SSC:

M. Blombäck, Department of Clinical Chemistry and Blood Coagulation, Karolinska Hospital, Stockholm, Sweden

Chairs and co-chairs of the SSC's scientific subcommittees¹:

U. Abildgaard, A. M. H. P. van den Besselaar, K. J. Clementson, B. Dahlbäck, T. Exner, C. W. Francis, P. Gaffney, H. Gralnick, L. W. Hoyer, G. J. Johnson, C. Kasper, D. Lane, H. R. Lijnen, J. M. Lusher, P. M. Mannucci, L. Poller, S. I. Rapaport, H. Saito, K. Stocker, D. Thomas.

Ad hoc consultants²: T. W. Barrowcliffe, C. Hemker, S. Thorsen, Chairman of the SSC:

D. Aronson, Past-Chairman of the ISTH: K. G. Mann, Chairman of the ISTH:

Dominique Meyer, Executive Director of ISTH and SSC: H. R. Roberts.

IUPAC, Commission on Quantities and Units in Clinical Chemistry and IFCC, Committee on Quantities and Units: R. Dybkær, K. Jørgensen, H. Olesen.

From the ¹Medical Department A, Aker Hospital, Norway; and Haemostasis and Thrombosis Research Center, Univ. Hospital Leiden, The Netherlands; and Theodor Kocher Institute, Univ. of Bern, Switzerland; and Dept. for Coagulation Disorders, Univ. of Lund, Sweden; and Haematology Dept., Westmead Hospital, Sydney, Australia; and Dept. of Medicine, Univ. of Rochester, New York, USA; and NIBSC, Hertfordshire, United Kingdom; and Hematology Service, NIH, Bethesda, Maryland, USA; and American Red Cross Holland Lab., Bethesda, Maryland, USA; and Univ. of Minnesota School VA Hospital, Minneapolis, USA; and Orthopedic Hospital, Los Angeles, California, USA; and Dept. of Haematology, Charing Cross and Westminster Medical School, London, United Kingdom; and Ctr. for Molecular and Vascular Biology, Leuven, Belgium; and Childrens Hospital of Michigan, Detroit, Michigan, USA; and Hemophilia Thrombosis Centre, Milano, Italy; and UK Ref. Lab for Anticoagulant Reagents and Control, Withington Hospital, Manchester, United Kingdom; and USCD, Med. Ctr., Univ. California, USA; and 1st Dept. of Int. Med., Nagoya Univ., Japan; and Pentapharm AG, Basel, Switzerland; and Bio Products Lab., Hertfordshire, United Kingdom, and

²NIBSC, Hertfordshire, United Kingdom; and Cardiovascular Res. Institute, Maastricht, The Netherlands; and Dept. Clin. Biochem., Univ. Hospital of Copenhagen, Denmark; and George Washington University School of Medicine, Washington, DC, USA; and Hôpital de Bicêtre, France; and International Headquarters of ISTH, UNC Med. School, Chapel Hill, North Carolina, USA; and Dept. Clin. Chem., Frederiksberg Hospital, Copenhagen, Denmark; and Dept. of Clin. Biochem., Univ. Hospital of Copenhagen, Denmark

Foreword

This document is a result of cooperation between the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis and The Committee/Commission on Quantities and Units (in Clinical Chemistry) of The International Federation of

Clinical Chemistry (IFCC) and The International Union of Pure and Applied Chemistry (IUPAC). Meetings between the organizations were held in Amsterdam (NL) 1991-06-29/30 and in Munich (D) 1992-07-07/08.

Introduction

Basic research in biology and medicine and innovations in laboratory methodology have greatly increased the range of quantities available

Correspondence to: Dr. H. Olesen, Department of Clin. Biochem. KB 76.4.2 Rigshospitalet, Tagensvej 20, DK-2200 Denmark

EXAMPLES

Entry:

- 1 **Plasma-**
- 3 **Plasminogen activator, tissue type;**
- 4 **substance concentration**(enz.; procedure)
- 5 P – Plasminogen activator, tissue type; subst. c.
(enz., IS 86/670) = 1 int. unit/l
- 6 $M = 60,000$ g/mol
- 7 Calibrator: WHO 2nd IS 86/670
- 8 Previous calibrator(s): WHO 1st IS 83/517
- 9 Not recommended term(s): Blood plasminogen activator;
t-PA; Tissue plasminogen activator; Vascular plasminogen
activator
- 10 Authority: Isth/SSC93

Entry:

- 1 **Plasma-**
- 2 α_2 -
- 3 **Macroglobulin:**
- 4 **substance concentration**
- 5 P – α_2 -Macroglobulin, subst. c. = $3.7 \mu\text{mol/l}$
- 6 $M = 725,000$ g/mol

Abbreviations

CAS	Chemical Abstract Service
EC	Enzyme Commission (of the International Union of Biochemistry and Molecular Biology)
ICW	International Complement Workshop
IFCC	International Federation of Clinical Chemistry
INR	International Normalized Ratio
IRP	International Reference Preparation
IS	International Standard (by WHO)
ISTH	International Society of Thrombosis and Haemostasis
IUPAC	International Union of Pure and Applied Chemistry
NIBSC	National Institute for Biological Standards and Control
NIH	National Institute of Health (USA)
SI	International System of Units
SSC	Scientific and Standardization Committee (of Isth)
WHO	World Health Organization

Bibliography

1. Dybkaer R, Jørgensen K. Measurement, value and scale. *Scand J Clin Lab Invest* 49, Suppl 194: 69–76, 1989.
2. International Union of Pure and Applied Chemistry and International Federation of Clinical Chemistry. Commission/Committee on Quantities and Units (in Clinical Chemistry). A proposal for a IUPAC-IFCC Recommendation. Quantities and Units in Clinical Laboratory Sciences. Mail ballot 1994–01.
3. Twelfth International Congress of Anatomists in London, 1985. *Nomina Anatomica*, 6th ed. Prepared by the International Anatomical Nomenclature Committee. London: Churchill Livingstone, 1989.
4. WHO (World Health Organization). The SI for the Health Professions. Prepared at the request of the Thirtieth World Health Assembly. Geneva: WHO, 1977.

Annex (Recommendation 1993)

Alphabetic list of Generic Quantities in Thrombosis and Haemostasis

Note 1

Kind-of-quantity. General nature of a *measurable quantity* defined by how *measurable quantities* of a system and its components are to be related in order to obtain a *value* of the *quantity*.

EXAMPLES

length, amount-of-substance, volume fraction.

Note 2

Threshold. Modifier indicating that a kind-of-quantity is defined as the lowest value of a quantity eliciting a reaction given by the component and specified by the procedure.

Note 3

Abbreviations for specifications. coag.: coagulation; coag. diss.: coagulum dissolution; enz.: enzymatic; imm.: immunological; imm. blott.: immunoblotting.

Note 4

Specifications necessary or useful for the interpretation of results are stated in the parenthesis following the kind-of-quantity. In the entries such specifications are indicated in the general sequence: analytical principle (coag., enz., imm., etc.); procedure (to be substituted by a recognized procedural name, e. g. the name of a commercial “kit”); further optional data, e. g. the calibrator used or the scale of possible results.

As apparent from the petit examples the choice of such specifications is more or less arbitrary.

Note 5

Abbreviation for activated component: a

EXAMPLES

Coagulation factor V,a; protein C,a inhibition.

Platelets–

Aggregation, ADP-induced;

threshold substance concentration(procedure)

Plts – Aggregation, ADP-induced; threshold subst.c.(procedure;
0 0.5 1 2 5 10 20 $\mu\text{mol/l}$) = 10 $\mu\text{mol/l}$

Authority: Isth/SSC93

Thrombocytes–

Aggregation, ADP-induced;

threshold substance concentration(procedure)

Trcs – Aggregation, ADP-induced; threshold subst.c.(procedure;
0 0.5 1 2 5 10 20 $\mu\text{mol/l}$) = 10 $\mu\text{mol/l}$

Authority: Isth/SSC93

Platelets–

Aggregation, adrenaline-induced;

threshold substance concentration(procedure)

Plts – Aggregation, adrenaline-induced; threshold subst.c.(procedure;
0 0.5 1 2 5 10 20 $\mu\text{mol/l}$) = 2 $\mu\text{mol/l}$

Authority: Isth/SSC93

Thrombocytes–

Aggregation, adrenaline-induced;

threshold substance concentration(procedure)

Trcs–Aggregation, adrenaline-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 2 µmol/l
Authority: Isth/SSC93

Platelets–

Aggregation, arachidonate-induced;

threshold substance concentration(procedure)

Plts–Aggregation, arachidonate-induced; threshold subst.c.(procedure) = a µmol/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, arachidonate-induced;

threshold substance concentration(procedure)

Trcs–Aggregation, arachidonate-induced; threshold subst.c.(procedure) = a µmol/l

Authority: Isth/SSC93

Platelets–

Aggregation, calcium ionophore-induced;

threshold substance concentration(procedure)

Plts–Aggregation, calcium ionophore-induced; threshold subst.c.(procedure) = a µmol/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, calcium ionophore-induced;

threshold substance concentration(procedure)

Trcs–Aggregation, calcium ionophore-induced; threshold subst.c.(procedure) = a µmol/l

Authority: Isth/SSC93

Platelets–

Aggregation, collagen-induced;

threshold mass concentration(procedure)

Plts–Aggregation, collagen-induced; threshold massc. (procedure; 0 0.5 1 2 5 10 20 mg/l) = 2 mg/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, collagen-induced;

threshold mass concentration(procedure)

Trcs–Aggregation, collagen-induced; threshold massc. (procedure; 0 0.5 1 2 5 10 20 mg/l) = 2 mg/l

Authority: Isth/SSC93

Platelets–

Aggregation, noradrenaline-induced;

threshold substance concentration(procedure)

Plts–Aggregation, noradrenaline-induced; threshold subst.c. (procedure; 0 5 10 20 50 200 µmol/l) = 20 µmol/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, noradrenaline-induced;

threshold substance concentration(procedure)

Trcs–Aggregation, noradrenaline-induced; threshold subst.c. (procedure; 0 5 10 20 50 200 µmol/l) = 20 µmol/l

Authority: Isth/SSC93

Platelets–

Aggregation, ristocetin-induced;

threshold mass concentration(procedure)

Plts–Aggregation, ristocetin-induced; threshold massc. (procedure; 0 1 2 g/l) = 1 g/l
Authority: Isth/SSC93

Thrombocytes–

Aggregation, ristocetin-induced;

threshold mass concentration(procedure)

Trcs–Aggregation, ristocetin-induced; threshold massc. (procedure; 0 1 2 g/l) = 1 g/l

Authority: Isth/SSC93

Platelets–

Aggregation, serotonin-induced;

threshold substance concentration(procedure)

Plts–Aggregation, serotonin-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 5 µmol/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, serotonin-induced;

threshold substance concentration(procedure)

Trcs–Aggregation, serotonin-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 5 µmol/l

Authority: Isth/SSC93

Platelets–

Aggregation, thrombin-induced;

threshold concentration(procedure)

Plts–Aggregation, thrombin-induced; threshold conc. (procedure; 0 20 50 100 200 500 1000 arb. unit/l) = 200 arb. unit/l

Authority: Isth/SSC93

Thrombocytes–

Aggregation, thrombin-induced;

threshold concentration(procedure)

Trcs–Aggregation, thrombin-induced; threshold conc. (procedure; 0 20 50 100 200 500 1000 arb. unit/l) = 200 arb. unit/l

Authority: Isth/SSC93

Plasma–

Antithrombin;

arbitrary substance concentration(enz.; procedure)

P–Antithrombin; arb. subst. c. (enz.; IRP 72/1) = 1 k(int. unit)/l

M = 65,000 g/mol

Calibrator: WHO 1st IRP 72/1

Not recommended term(s): Antithrombin III; Heparin cofactor I; Thrombin inhibitor I

Authority: Isth/SSC93

Plasma–

Antithrombin;

substance concentration(enz.; procedure)

P–Antithrombin; subst. c. (enz.; procedure) = 2.5 µmol/l

M = 65,000 g/mol

Not recommended term(s): Antithrombin III; Heparin cofactor I; Thrombin inhibitor I

Authority: Isth/SSC93

Trcs-Aggregation, adrenaline-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 2 µmol/l

Authority: ISTH/SSC93

Platelets-

Aggregation, arachidonate-induced;

threshold substance concentration(procedure)

Plts-Aggregation, arachidonate-induced; threshold subst.c.(procedure) = a µmol/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, arachidonate-induced;

threshold substance concentration(procedure)

Trcs-Aggregation, arachidonate-induced; threshold subst.c.(procedure) = a µmol/l

Authority: ISTH/SSC93

Platelets-

Aggregation, calcium ionophore-induced;

threshold substance concentration(procedure)

Plts-Aggregation, calcium ionophore-induced; threshold subst.c.(procedure) = a µmol/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, calcium ionophore-induced;

threshold substance concentration(procedure)

Trcs-Aggregation, calcium ionophore-induced; threshold subst.c.(procedure) = a µmol/l

Authority: ISTH/SSC93

Platelets-

Aggregation, collagen-induced;

threshold mass concentration(procedure)

Plts-Aggregation, collagen-induced; threshold massc. (procedure; 0 0.5 1 2 5 10 20 mg/l) = 2 mg/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, collagen-induced;

threshold mass concentration(procedure)

Trcs-Aggregation, collagen-induced; threshold massc. (procedure; 0 0.5 1 2 5 10 20 mg/l) = 2 mg/l

Authority: ISTH/SSC93

Platelets-

Aggregation, noradrenaline-induced;

threshold substance concentration(procedure)

Plts-Aggregation, noradrenaline-induced; threshold subst.c. (procedure; 0 5 10 20 50 200 µmol/l) = 20 µmol/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, noradrenaline-induced;

threshold substance concentration(procedure)

Trcs-Aggregation, noradrenaline-induced; threshold subst.c. (procedure; 0 5 10 20 50 200 µmol/l) = 20 µmol/l

Authority: ISTH/SSC93

Platelets-

Aggregation, ristocetin-induced;

threshold mass concentration(procedure)

Plts-Aggregation, ristocetin-induced; threshold massc. (procedure; 0 1 2 g/l) = 1 g/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, ristocetin-induced;

threshold mass concentration(procedure)

Trcs-Aggregation, ristocetin-induced; threshold massc. (procedure; 0 1 2 g/l) = 1 g/l

Authority: ISTH/SSC93

Platelets-

Aggregation, serotonin-induced;

threshold substance concentration(procedure)

Plts-Aggregation, serotonin-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 5 µmol/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, serotonin-induced;

threshold substance concentration(procedure)

Trcs-Aggregation, serotonin-induced; threshold subst.c.(procedure; 0 0.5 1 2 5 10 20 µmol/l) = 5 µmol/l

Authority: ISTH/SSC93

Platelets-

Aggregation, thrombin-induced;

threshold concentration(procedure)

Plts-Aggregation, thrombin-induced; threshold conc. (procedure; 0 20 50 100 200 500 1000 arb. unit/l) = 200 arb. unit/l

Authority: ISTH/SSC93

Thrombocytes-

Aggregation, thrombin-induced;

threshold concentration(procedure)

Trcs-Aggregation, thrombin-induced; threshold conc. (procedure; 0 20 50 100 200 500 1000 arb. unit/l) = 200 arb. unit/l

Authority: ISTH/SSC93

Plasma-

Antithrombin;

arbitrary substance concentration(enz.; procedure)

P-Antithrombin; arb. subst. c. (enz.; IRP 72/1) = 1 k(int. unit)/l

M = 65,000 g/mol

Calibrator: WHO 1st IRP 72/1

Not recommended term(s): Antithrombin III; Heparin cofactor I; Thrombin inhibitor I

Authority: ISTH/SSC93

Plasma-

Antithrombin;

substance concentration(enz.; procedure)

P-Antithrombin; subst. c. (enz.; procedure) = 2.5 µmol/l

M = 65,000 g/mol

Not recommended term(s): Antithrombin III; Heparin cofactor I; Thrombin inhibitor I

Authority: ISTH/SSC93

Plasma–
Antithrombin;
 substance concentration(imm.; procedure)
 P–Antithrombin; subst.c.(imm.; procedure) = 2.5 µmol/l
 M = 65,000 g/mol
 Not recommended term(s): Antithrombin III; Heparin cofactor I;
 Thrombin inhibitor I
 Authority: ISTH/SSC93

Plasma–
Antithrombin;
 arbitrary substance concentration(imm.; procedure)
 P–Antithrombin; arb. subst.c.(imm.; IRP 72/1) = 1 k(int. unit)/l
 M = 65,000 g/mol
 Calibrator: WHO 1st IRP 72/1
 Not recommended term(s): Antithrombin III; Heparin cofactor I;
 Thrombin inhibitor I
 Authority: ISTH/SSC93

Plasma–
Apolipoprotein H;
 substance concentration
 P–Apolipoprotein H; subst.c.= a mol/l
 Not recommended term(s): β-2-glycoprotein 1
 Authority: IFCC–IUPAC94

Plasma–
Calcium ion(free);
 substance concentration
 P–Calcium ion(free); subst.c.= 1.22 µmol/l
 M = 40.080 g/mol
 Not recommended term(s): Coagulation factor IV
 Authority: IFCC–IUPAC94

Patient–
Capillary bleeding;
 time (procedure)
 Pt–Capillary bleeding; time (template) = 300 s
 Not recommended term(s): Bleeding time
 Authority: ISTH/SSC93

Plasma–
Cardiolipin antibody;
 arbitrary substance concentration(procedure)
 P–Cardiolipin antibody; arb. subst.c.(procedure) = a arb. unit/l
 Authority: IFCC–IUPAC94

Blood–
Coagulation;
 time (procedure)
 B–Coagulation; time (procedure) = 400 s
 Not recommended term(s): Coagulation time
 Authority: ISTH/SSC93

Plasma–
Coagulation, calcium ion-induced;
 time (procedure)
 P–Coagulation, calcium ion-induced; time (procedure) = 90 s
 Not recommended term(s): Recalcification time
 Authority: ISTH/SSC93

Plasma–
Coagulation, ecarin-induced;
 time (procedure)
 P–Coagulation, ecarin-induced; time (procedure) = a s
 Authority: ISTH/SSC93
 Note: The name ecarin is derived from EC 3.4.99.27
 Echis carinatus prothrombin-activating proteinase

Plasma–
Coagulation, batroxobin-induced;
 time (procedure)
 P–Coagulation, batroxobin-induced; time (procedure) = 15 s
 Authority: ISTH/SSC93
 Note: The name batroxobin is derived from EC 3.4.21.29
 Bothrops atrox serine proteinase

Plasma–
Coagulation, russelactivase X-induced;
 time (procedure)
 P–Coagulation, russelactivase X-induced; time (procedure) = 30 s
 Authority: ISTH/SSC93
 Note: The name russelactivase X is derived from *Vipera russelli*
 venom

Plasma–
Coagulation, surface-induced;
 inverse relative time (procedure; norm/actual)
 P–Coagulation, surface-induced; inverse rel. time (procedure;
 norm/actual) = 0.44
 Not recommended term(s): Activated partial thromboplastin time;
 aPTT; APTT
 Authority: ISTH/SSC93

Plasma–
Coagulation, surface-induced;
 relative time (procedure; actual/norm)
 P–Coagulation, surface-induced; rel. time (procedure; actual/
 norm) = 2.3
 Not recommended term(s): Activated partial thromboplastin time;
 aPTT; APTT
 Authority: ISTH/SSC93

Plasma–
Coagulation, surface-induced;
 time (procedure)
 P–Coagulation, surface-induced; time (procedure) = 30 s
 Not recommended term(s): Activated partial thromboplastin time;
 aPTT; APTT
 Authority: ISTH/SSC93

Plasma–
Coagulation, thrombin-induced;
 time (procedure)
 P–Coagulation, thrombin-induced; time (procedure) = 15 s
 Not recommended term(s): Thrombin time
 Authority: ISTH/SSC93

Calibrator: WHO IS 84/665

Not recommended term(s): Serum prothrombin conversion accelerator; Proconvertin; SPCA

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII;

relative substance concentration(actual/norm)

P–Coagulation factor VII; rel. subst.c.(actual/norm) = 0.8

$M = 48,000$ g/mol

Not recommended term(s): Serum prothrombin conversion accelerator; Proconvertin; SPCA

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII;

substance concentration(imm.; procedure)

P–Coagulation factor VII; subst.c.(imm.; procedure) = 10 nmol/l

$M = 48,000$ g/mol

Not recommended term(s): Serum prothrombin conversion accelerator; Proconvertin; SPCA

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII, activated;

arbitrary substance concentration(coag.; procedure)

P–Coagulation factor VII, a; arb. subst.c.(coag.; procedure) = a arb. unit/l

$M = 48,000$ g/mol

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII+acarboxy;

relative substance concentration(imm.; actual/norm)

P–Coagulation factor VII+acarboxy; rel. subst.c.(imm.; actual/norm) = 1.1

$M = 48,000$ g/mol

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII+acarboxy;

substance concentration(imm.; procedure)

P–Coagulation factor VII+acarboxy; subst.c.(imm.; procedure) = 10 nmol/l

$M = 48,000$ g/mol

Authority: ISTH/SSC93

Plasma–

Coagulation factor VII antibody;

arbitrary substance concentration(coag.; procedure)

P–Coagulation factor VII antibody; arb. subst.c.(coag.; procedure) = 0.1 arb. unit = 0 arb. unit

Not recommended term(s): Coagulation factor VII inhibitor

Authority: ISTH/SSC93

Plasma–

Coagulation factor VIII;

arbitrary substance concentration(coag.; procedure)

P–Coagulation factor VIII; arb. subst.c.(coag.; IS 91/666) = 1 k(int. unit)/l

$M = 330,000$ g/mol

Calibrator: WHO 3rd IS 91/666

Previous calibrator(s): WHO 2nd IS 87/718

Not recommended term(s): VIII:C; Antihemophilic factor; AHF; Antihemophilic globulin; AHG; Factor VIII clotting activity; Thrombocyte cofactor A

Authority: ISTH/SSC93

Plasma–

Coagulation factor VIII;

arbitrary substance concentration(enz.; procedure)

P–Coagulation factor VIII; arb. subst.c.(enz.; Xa activator; IS 91/666) = 1 k(int. unit)/l

$M = 330,000$ g/mol

Calibrator: WHO 3rd IS 91/666

Previous calibrator(s): WHO 2nd IS 87/718

Not recommended term(s): VIII:C; Antihemophilic factor; AHF; Antihemophilic globulin; AHG; Factor VIII clotting activity; Thrombocyte cofactor A

Authority: ISTH/SSC93

Plasma–

Coagulation factor VIII;

arbitrary substance concentration(imm.; procedure)

P–Coagulation factor VIII; arb. subst.c.(imm.; IS 91/666) = 1 k(int. unit)/l

$M = 330,000$ g/mol

Calibrator: WHO 3rd IS 91/666

Previous calibrator(s): WHO 2nd IS 87/718

Not recommended term(s): VIII:C; Antihemophilic factor; AHF; Antihemophilic globulin; AHG; Factor VIII:Ag; Factor VIII clotting activity; Thrombocyte cofactor A

Authority: ISTH/SSC93

Plasma–

Coagulation factor VIII;

substance concentration(imm.; procedure)

P–Coagulation factor VIII; subst.c.(imm.; procedure) = 0.3 nmol/l

$M = 330,000$ g/mol

Not recommended term(s): VIII:Ag; Antihemophilic factor; AHF; Antihemophilic globulin; AHG; Factor VIII:Ag; Factor VIII clotting activity; Thrombocyte cofactor A

Authority: ISTH/SSC93

Plasma–

Coagulation factor VIII, activated;

arbitrary substance concentration(coag.; procedure)

P–Coagulation factor VIII,a; arb. subst.c.(coag.; procedure) = a int. unit/l

$M = 330,000$ g/mol

Authority: ISTH/SSC93

Plasma—
Coagulation factor VIII antibody;
arbitrary substance concentration(coag.; procedure)
P—Coagulation factor VIII antibody; arb. subst.c.(coag.; Bethesda; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Circulating anticoagulant; Coagulation factor VIII inhibitor
Authority: ISTH/SSC93
Note: Possible procedures: Bethesda; modified Bethesda; Oxford old; Oxford new, etc.

Plasma—
Coagulation factor VIII antibody;
arbitrary substance concentration(enz.; procedure)
P—Coagulation factor VIII antibody; arb. subst.c.(enz.; procedure; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Circulating anticoagulant; Coagulation factor VIII inhibitor
Authority: ISTH/SSC93

Plasma—
Coagulation factor VIII antibody;
arbitrary substance concentration(imm.; procedure)
P—Coagulation factor VIII antibody; arb. subst.c.(imm.; procedure; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Circulating anticoagulant; Coagulation factor VIII inhibitor
Authority: ISTH/SSC93

Plasma—
Coagulation factor IX;
arbitrary substance concentration(coag.; procedure)
P—Coagulation factor IX; arb. subst.c.(coag.; IS 84/665) = a int. unit/l
 $M = 55,400$ g/mol
Calibrator: WHO IS 84/665
Not recommended term(s): Antihemophilic factor B; Christmas factor; Plasma thromboplastin component; PTC; Thrombocyte co-factor II
Authority: ISTH/SSC93

Plasma—
Coagulation factor IX;
arbitrary substance concentration(enz.; procedure)
P—Coagulation factor IX; arb. subst.c.(enz.; IS 84/665) = a int. unit/l
 $M = 55,400$ g/mol
Calibrator: WHO IS 84/665
Not recommended term(s): Antihemophilic factor B; Christmas factor; Plasma thromboplastin component; PTC; Thrombocyte co-factor II
Authority: ISTH/SSC93

Plasma—
Coagulation factor IX;
relative substance concentration(imm.; actual/norm)
P—Coagulation factor IX; rel. subst.c.(imm.; actual/norm) = 1
 $M = 55,400$ g/mol
Not recommended term(s): Antihemophilic factor B; Christmas factor; Plasma thromboplastin component; PTC; Thrombocyte co-

factor II; Factor IX:Ag
Authority: ISTH/SSC93

Plasma—
Coagulation factor IX;
substance concentration(imm.; procedure)
P—Coagulation factor IX; subst.c.(imm.; procedure) = 80 nmol/l
 $M = 55,400$ g/mol
Not recommended term(s): Antihemophilic factor B; Christmas factor; Plasma thromboplastin component; PTC; Thrombocyte co-factor II; Factor IX:Ag
Authority: ISTH/SSC93

Plasma—
Coagulation factor IX, activated;
arbitrary substance concentration(coag.; procedure)
P—Coagulation factor IX,a; arb. subst.c.(coag.; procedure) = a arb. unit/l
 $M = 55,400$ g/mol
Authority: IFCC92

Plasma—
Coagulation factor IX antibody;
arbitrary substance concentration(coag.; procedure)
P—Coagulation factor IX antibody; arb. subst.c.(coag.; Bethesda modified; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Coagulation factor IX inhibitor
Authority: ISTH/SSC93

Plasma—
Coagulation factor X;
arbitrary substance concentration(coag.; procedure)
P—Coagulation factor X; arb. subst.c.(coag.; IS 84/665) = 1 k (int. unit)/l
 $M = 59,000$ g/mol
Calibrator: WHO 1st IS 84/665
Not recommended term(s): Autoprothrombin III; Prothrombokinase; Stuart-Prower factor
Authority: ISTH/SSC93

Plasma—
Coagulation factor X;
arbitrary substance concentration(enz.; procedure)
P—Coagulation factor X; arb. subst.c.(enz.; IS 84/665) = 1 k (int. unit)/l
 $M = 59,000$ g/mol
Calibrator: WHO 1st IS 84/665
Not recommended term(s): Autoprothrombin III; Prothrombokinase; Stuart-Prower factor
Authority: ISTH/SSC93

Plasma—
Coagulation factor X;
relative substance concentration(imm.; actual/norm)
P—Coagulation factor X; rel. subst.c.(imm.; actual/norm) = 0.8
 $M = 59,000$ g/mol
Not recommended term(s): Autoprothrombin III; Prothrombokinase; Stuart-Prower factor
Authority: ISTH/SSC93

Plasma–
Coagulation factor X;
substance concentration(imm.; procedure)
P–Coagulation factor X; subst.c.(imm.; procedure) = 160 nmol/l
 $M = 59,000$ g/mol
Not recommended term(s): Autoprothrombin III; Prothrombokinase; Stuart-Prower factor
Authority: ISTH/SSC93

Plasma–
Coagulation factor X, activated;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor X_a; arb. subst.c.(coag.; procedure) = a arb. unit/l
 $M = 59,000$ g/mol
Authority: ISTH/SSC93

Plasma–
Coagulation factor X+acarboxy;
relative substance concentration(imm.; actual/norm)
P–Coagulation factor X+acarboxy; rel. subst.c.(imm.; actual/norm) = 1
 $M = 59,000$ g/mol
Authority: ISTH/SSC93

Plasma–
Coagulation factor X+acarboxy;
substance concentration(imm.; procedure)
P–Coagulation factor X+acarboxy; subst.c.(imm.; procedure) = 160 nmol/l
 $M = 59,000$ g/mol
Authority: ISTH/SSC93

Plasma–
Coagulation factor X antibody;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor X antibody; arb. subst.c.(coag.; procedure; 0.1 arb. unit) = 0 arb. unit
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor XI; arb. subst.c.(coag.; procedure) = a arb. unit/l
 $M = 160,000$ g/mol
Not recommended term(s): Antihemophilic factor C; Plasma thromboplastin antecedent; PTA
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI;
arbitrary substance concentration(enz.; procedure)
P–Coagulation factor XI; arb. subst.c.(enz.; procedure) = a arb. unit/l
 $M = 160,000$ g/mol
Not recommended term(s): Antihemophilic factor C; Plasma thromboplastin antecedent; PTA
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI;
relative substance concentration(imm.; actual/norm)
P–Coagulation factor XI; rel. subst.c.(imm.; actual/norm) = 1
 $M = 160,000$ g/mol
Not recommended term(s): Antihemophilic factor C; Plasma thromboplastin antecedent; PTA
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI;
substance concentration(imm.; procedure)
P–Coagulation factor XI; subst.c.(imm.; procedure) = 30 nmol/l
 $M = 160,000$ g/mol
Not recommended term(s): Antihemophilic factor C; Plasma thromboplastin antecedent; PTA
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI, activated;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor XI_a; arb. subst.c.(coag.; procedure) = a arb. unit/l
 $M = 160,000$ g/mol
Authority: ISTH/SSC93

Plasma–
Coagulation factor XI antibody;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor XI antibody; arb. subst.c.(coag.; procedure; 0.1 arb. unit) = 0 arb. unit
Not recommended term(s): Coagulation factor XI inhibitor
Authority: ISTH/SSC93

Plasma–
Coagulation factor XII;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor XII; arb. subst.c.(coag.; procedure) = 1 k (arb. unit)/l
 $M = 80,000$ g/mol
Not recommended term(s): Hageman factor
Authority: ISTH/SSC93

Plasma–
Coagulation factor XII;
arbitrary substance concentration(enz.; procedure)
P–Coagulation factor XII; arb. subst.c.(enz.; procedure) = 1 k (arb. unit)/l
 $M = 80,000$ g/mol
Not recommended term(s): Hageman factor
Authority: ISTH/SSC93

Plasma–
Coagulation factor XII;
relative substance concentration(imm.; actual/norm)
P–Coagulation factor XII; rel. subst.c.(imm.; actual/norm) = 0.8
 $M = 80,000$ g/mol
Not recommended term(s): Hageman factor
Authority: ISTH/SSC93

Plasma—
Coagulation factor XII;
substance concentration(imm.; procedure)
P–Coagulation factor XII; subst.c.(imm.; procedure) = 370 nmol/l
 $M = 80,000$ g/mol
Not recommended term(s): Hageman factor
Authority: ISTH/SSC93

Plasma—
Coagulation factor XII, activated;
arbitrary substance concentration(coag.; procedure)
P–Coagulation factor XII,a; arb. subst.c.(coag.; procedure) = a arb. unit/l
 $M = 80,000$ g/mol
Authority: ISTH SSC93

Plasma—
Coagulation factor XII antibody;
arbitrary substance concentration(coag. procedure)
P–Coagulation factor XII antibody; arb. subst.c.(coag.; procedure; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Coagulation factor XII inhibitor
Authority: ISTH/SSC93

Plasma—
Coagulation factor XIII;
arbitrary substance concentration(coag. diss.; procedure)
P–Coagulation factor XIII; arb. subst.c.(coag. diss.; procedure) = 1 arb. unit/l
 $M = 320,000$ g/mol
Not recommended term(s): Fibrin stabilizing factor; Fibrinolygase; Fibrinase Laki-Lorand factor; Plasma transglutaminase; Plasma transamidase; Protransglutaminase
Authority: ISTH/SSC93

Plasma—
Coagulation factor XIII;
relative substance concentration(imm.; actual/norm)
P–Coagulation factor XIII; rel. subst.c.(imm.; actual/norm) = 1
 $M = 320,000$ g/mol
Not recommended term(s): Fibrin stabilizing factor; Fibrinolygase; Fibrinase Laki-Lorand factor; Plasma transglutaminase; Plasma transamidase; Protransglutaminase
Authority: ISTH/SSC93

Plasma—
Coagulation factor XIII;
substance concentration(imm.; procedure)
P–Coagulation factor XIII; subst.c.(imm.; procedure) = 90 nmol/l
 $M = 320,000$ g/mol
Not recommended term(s): Fibrin stabilizing factor; Fibrinolygase; Fibrinase Laki-Lorand factor; Plasma transglutaminase; Plasma transamidase; Protransglutaminase
Authority: ISTH/SSC93

Plasma—
Coagulation factor XIII, activated;
arbitrary substance concentration(procedure)
P–Coagulation factor XIII,a; arb. subst.c.(procedure) = a arb. unit/l

$M = 320,000$ g/mol
Authority: ISTH/SSC93

Plasma—
Coagulation factor XIII antibody;
arbitrary substance concentration(procedure)
P–Coagulation factor XIII antibody; arb. subst.c.(procedure; 0 1 arb. unit) = 0 arb. unit
Not recommended term(s): Coagulation factor XIII inhibitor
Authority: ISTH/SSC93

Plasma—
Coagulum lysis;
time (coag. diss.; procedure)
P–Coagulum lysis; time (coag. diss.; procedure) = 6 ks
Not recommended term(s): Euglobulin clot lysis time
Authority: ISTH/SSC93

Blood –
Coagulum retraction;
volume fraction change (procedure)
B–Coagulum retraction; vol.fr. change (procedure) = a
Authority: ISTH/SSC93

Plasma—
Complement C1 esterase inhibitor;
arbitrary substance concentration(enz.; procedure)
P–Complement C1 esterase inhibitor; arb. subst.c.(enz.; procedure) = a arb. unit/l
 $M = 105,000$ g/mol
Not recommended term(s): C1 Inactivator; C1 INA; C1IA; C1 esterase inhibitor; C1 INH; C1 inhibitor
Authority: ICW91

Plasma—
Complement C1 esterase inhibitor;
arbitrary substance concentration(imm.; procedure)
P–Complement C1 esterase inhibitor; arb. subst.c.(imm.; procedure) = a arb. unit/l
 $M = 105,000$ g/mol
Not recommended term(s): C1 Inactivator; C1 INA; C1IA; C1 esterase inhibitor; C1 INH; C1 inhibitor
Authority: ICW91

Plasma—
Complement C1 esterase inhibitor;
substance concentration(imm.; procedure)
P–Complement C1 esterase inhibitor; subst.c.(imm.; procedure) = 2.3 μ mol/l
 $M = 105,000$ g/mol
Not recommended term(s): C1 Inactivator; C1 INA; C1IA; C1 esterase inhibitor; C1 INH; C1 inhibitor
Authority: ICW91

Platelets—
Connective tissue-activating peptide 3;
arbitrary substance concentration(enz.; procedure)
Plts–Connective tissue-activating peptide 3; arb. subst. c. (enz.; procedure) = a arb. unit/l
Authority: ISTH/SSC93

Thrombocytes–
Connective tissue-activating peptide 3;
arbitrary substance concentration(enz.; procedure)
Trcs–Connective tissue-activating peptide 3; arb. subst. c. (enz.; procedure) = arb. unit/l
Authority: Isth/SSC93

Platelets–
Connective tissue-activating peptide 3;
arbitrary substance concentration(imm.; procedure)
Plts–Connective tissue-activating peptide 3; arb. subst. c. (imm.; procedure) = arb. unit/l
Authority: Isth/SSC93

Thrombocytes–
Connective tissue-activating peptide 3;
arbitrary substance concentration(imm.; procedure)
Trcs–Connective tissue-activating peptide 3; arb. subst. c. (imm.; procedure) = a arb. unit/l
Authority: Isth/SSC93

Plasma–
Fibrin+fibrinogen fragments;
arbitrary substance concentration(imm.; procedure)
P–Fibrin+fibrinogen fragments; arb. subst.c.(imm.; procedure) = a arb. unit
Not recommended term(s): FDP; Fibrinogen degradation products; Fibrinogen related antigens; Fibrinogen split products
Authority: Isth/SSC93

Plasma–
Fibrin, soluble;
arbitrary substance concentration(procedure)
P–Fibrin, soluble; arb. subst.c.(ethanol gelation; 0 1 arb. unit) = 0 arb. unit
Authority: Isth/SSC93

Plasma–
Fibrin, soluble;
arbitrary substance concentration(enz.; procedure)
P–Fibrin, soluble; arb. subst.c.(enz.; procedure) = 0 arb. unit/l
Authority: Isth/SSC93

Plasma–
Fibrin D-dimer;
substance concentration(imm.; procedure)
P–Fibrin D-dimer; subst.c.(imm.; procedure) = 1 nmol/l
 $M = 182,600 \text{ g/mol}$
Authority: Isth/SSC93

Plasma–
Fibrin fragments;
arbitrary substance concentration(imm.; procedure)
P–Fibrin fragments; arb. subst.c.(imm.; procedure) = a arb. unit/l
Authority: Isth/SSC93

Plasma–
Fibrinogen;
substance concentration(coag.; procedure)

P–Fibrinogen; subst.c.(coag.; IS 89/644) = 7 $\mu\text{mol/l}$
 $M = 340,000 \text{ g/mol}$
Calibrator: WHO IS 89/644
Not recommended term(s): Coagulation factor I
Authority: Isth/SSC93

Plasma–
Fibrinogen;
substance concentration(imm.; procedure)
P–Fibrinogen; subst.c.(imm.; procedure) = 7 $\mu\text{mol/l}$
 $M = 340,000 \text{ g/mol}$
Not recommended term(s): Coagulation factor I
Authority: Isth/SSC93

Plasma–
Fibrinogen fragments;
arbitrary substance concentration(procedure)
P–Fibrinogen fragments; arb. subst.c.(procedure) = a arb. unit/l
Authority: Isth/SSC93

Plasma–
Fibrinopeptide A;
substance concentration(imm.; procedure)
P–Fibrinopeptide A; subst.c.(imm.; procedure) < 2 nmol/l
 $M = 1,750 \text{ g/mol}$
Authority: Isth/SSC93

Plasma–
Fibrinopeptide B;
substance concentration(imm.; procedure)
P–Fibrinopeptide B; subst.c.(imm.; procedure) = a nmol/l
 $M = 1,543 \text{ g/mol}$
Authority: Isth/SSC93

Plasma–
Fibrinopeptide B β (1–14);
substance concentration(imm.; procedure)
P–Fibrinopeptide B β (1–14); subst.c.(imm.; procedure) = 0.5 nmol/l
 $M = 1,570.8 \text{ g/mol}$
Authority: Isth/SSC93

Plasma–
Fibrinopeptide B β (1–42);
substance concentration(imm.; procedure)
P–Fibrinopeptide B β (1–42); subst.c.(imm.; procedure) = 1.2 nmol/l
 $M = 4,592.7 \text{ g/mol}$
Authority: Isth/SSC93

Plasma–
Fibrinopeptide B β (15–42);
substance concentration(imm.; procedure)
P–Fibrinopeptide B β (15–42); subst.c.(imm.; procedure) = a nmol/l
 $M = 3,039.9 \text{ g/mol}$
Authority: Isth/SSC93

Plasma—
Lupus anticoagulant;
arbitrary substance concentration(procedure)
P–Lupus anticoagulant; arb. subst.c.(procedure; 0 1 arb. unit) =
0 arb. unit
Not recommended term(s): Coagulation inhibiting antibody; Lupus
inhibitor
Authority: ISTD/SSC93

Plasma—
 α 2-
Macroglobulin substance concentration;
P– α 2-Macroglobulin; subst.c.= 3.7 μ mol/l
 M = 725,000 g/mol
Authority: IFCC–IUPAC94

Platelets—
Neutrophilocyte-activating peptide 2;
arbitrary substance concentration(enz.; procedure)
Plts–Neutrophilocyte-activating peptide 2; arb. subst.c.(enz.; proce-
dure) = a arb. unit/l
Authority: ISTD/SSC93

Thrombocytes—
Neutrophilocyte-activating peptide 2;
arbitrary substance concentration(enz.; procedure)
Trcs–Neutrophilocyte-activating peptide 2; arb. subst.c.(enz.; proce-
dure) = a arb. unit/l
Authority: ISTD/SSC93

Platelets—
Neutrophilocyte-activating peptide 2;
arbitrary substance concentration(imm.; procedure)
Plts–Neutrophilocyte-activating peptide 2; arb. subst.c.(imm.; proce-
dure) = a arb. unit/l
Authority: ISTD/SSC93

Thrombocytes—
Neutrophilocyte-activating peptide 2;
arbitrary substance concentration(imm.; procedure)
Trcs–Neutrophilocyte-activating peptide 2; arb. subst.c.(imm.; proce-
dure) = a arb. unit/l
Authority: ISTD/SSC93

Plasma—
Plasmin inhibitor;
arbitrary substance concentration(enz.; procedure)
P–Plasmin inhibitor; arb. subst.c.(enz.; procedure) = a arb. unit/l
 M = 70,000 g/mol
Not recommended term(s): α 2-Antiplasmin; α 2-AP; Primary fibri-
nolysis inhibitor; Primary plasmin inhibitor
Authority: ISTD/SSC93

Plasma—
Plasmin inhibitor;
arbitrary substance concentration(imm.; procedure)
P–Plasmin inhibitor; arb. subst.c.(imm.; procedure) = a arb. unit/l
 M = 70,000 g/mol

Not recommended term(s): α 2-Antiplasmin; α 2-AP; Primary fibri-
nolysis inhibitor; Primary plasmin inhibitor
Authority: ISTD/SSC93

Plasma—
Plasmin inhibitor;
substance concentration(imm.; procedure)
P–Plasmin inhibitor; subst.c.(imm.; procedure) = 1.0 μ mol/l
 M = 70,000 g/mol
Not recommended term(s): α 2-Antiplasmin; α 2-AP; Primary fibri-
nolysis inhibitor; Primary plasmin inhibitor
Authority: ISTD/SSC93

Plasma—
Plasmin-Plasmin inhibitor complex;
substance concentration(imm.; procedure)
P–Plasmin-Plasmin inhibitor complex; subst.c.(imm.; procedure) =
1.0 nmol/l
 M = 140,000 g/mol
Not recommended term(s): Plasmin- α 2-Antiplasmin complex
Authority: ISTD/SSC93

Plasma—
Plasminogen;
arbitrary substance concentration(enz.; procedure)
P–Plasminogen; arb. subst.c.(enz.; 1st BR 78/646) = a arb. unit/l
 M (Glu-1 type) = 92,000 g/mol
Calibrator: 1st Br Ref Prep 78/646 (Glu-type)
Not recommended term(s): PLG; Plgn; Profibrinolysin
Authority: ISTD/SSC93

Plasma—
Plasminogen;
substance concentration(imm.; procedure)
P–Plasminogen; subst.c.(imm.; procedure) = 1.3 μ mol/l
 M (Glu-1 type) = 92,000 g/mol
Not recommended term(s): PLG; Plgn; Profibrinolysin
Authority: ISTD/SSC93

Plasma—
Plasminogen activator inhibitor 1;
arbitrary substance concentration(enz.; procedure)
P–Plasminogen activator inhibitor 1; arb. subst.c.(enz.; NIBSC
87/512) = 7 arb. unit/l
 M = 52,000 g/mol
Calibrator: NIBSC 87/512 (non-official)
Not recommended term(s): Endothelial cell type PAI; Fast acting
PAI; PAI 1; PA-inhibitor I; Platelet PAI; t-PA inhibitor
Authority: ISTD/SSC93

Plasma—
Plasminogen activator inhibitor 1;
arbitrary substance concentration(imm.; procedure)
P–Plasminogen activator inhibitor 1; arb. subst.c.(imm.; NIBSC
87/512) = 7 arb. unit/l
 M = 52,000 g/mol
Calibrator: NIBSC 87/512 (non-official)
Not recommended term(s): Endothelial cell type PAI; Fast acting
PAI; PAI 1; PA-inhibitor I; Platelet PAI; t-PA inhibitor
Authority: ISTD/SSC93

Plasma—
Plasminogen activator inhibitor 1;
substance concentration(imm.; procedure)
P-Plasminogen activator inhibitor 1; subst.c.(imm.; procedure) = 0.2 nmol/l
 $M = 52,000$ g/mol
Not recommended term(s): Endothelial cell type PAI; Fast acting PAI; PAI 1; PA-inhibitor I; Platelet PAI; t-PA inhibitor
Authority: ISTH/SSC93

Plasma—
Plasminogen activator inhibitor 1;
substance concentration(enz.; procedure)
P-Plasminogen activator inhibitor 1; subst.c.(enz.; procedure) = 0.2 nmol/l
 $M = 52,000$ g/mol
Not recommended term(s): Endothelial cell type PAI; Fast acting PAI; PAI 1; PA-inhibitor I; Platelet PAI; t-PA inhibitor
Authority: ISTH/SSC93

Plasma—
Plasminogen activator inhibitor 2;
arbitrary substance concentration(enz.; procedure)
P-Plasminogen activator inhibitor 2; arb. subst.c.(enz.; procedure) = a arb. unit/l
 $M = 60,000$ g/mol
Not recommended term(s): PA-inhibitor 2; Placental PAI; PAI 2; u-PA-inhibitor
Authority: ISTH/SSC93

Plasma—
Plasminogen activator inhibitor 2;
arbitrary substance concentration(imm.; procedure)
P-Plasminogen activator inhibitor 2; arb. subst.c.(imm.; procedure) = a arb. unit/l
 $M = 60,000$ g/mol
Not recommended term(s): PA-inhibitor 2; Placental PAI; PAI 2; u-PA-inhibitor
Authority: ISTH/SSC93

Plasma—
Plasminogen activator inhibitor 2;
substance concentration(imm.; procedure)
P-Plasminogen activator inhibitor 2; subst.c.(imm.; procedure) = a mol/l
 $M = 60,000$ g/mol
Not recommended term(s): PA-inhibitor 2; Placental PAI; PAI 2; u-PA-inhibitor
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
arbitrary substance concentration(enz.; procedure)
P-Plasminogen activator, tissue type; arb. subst.c.(enz.; IS 86/670) = 1 int. unit/l
 $M = 60,000$ g/mol
Calibrator: WHO 2nd IS 86/670
Previous calibrator(s): WHO 1st IS 83/517

Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
arbitrary substance concentration(stated time after venistasis; enz.; procedure)
P-Plasminogen activator, tissue type; arb. subst.c.(10 min after venistasis; enz.; IS 86/670) = a int. unit/l
 $M = 60,000$ g/mol
Calibrator: WHO 2nd IS 86/670
Previous calibrator(s): WHO 1st IS 83/517
Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
substance concentration(enz.; procedure)
P-Plasminogen activator, tissue type; subst.c.(enz.; procedure) = 15 pmol/l
 $M = 60,000$ g/mol
Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
substance concentration(imm.; procedure)
P-Plasminogen activator, tissue type; subst.c.(imm.; procedure) = 70 pmol/l
 $M = 60,000$ g/mol
Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
substance concentration(stated time after venistasis; enz.; procedure)
P-Plasminogen activator, tissue type; subst.c.(10 min after venistasis; enz.; procedure) = a pmol/l
 $M = 60,000$ g/mol
Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma—
Plasminogen activator, tissue type;
substance concentration(stated time after venistasis; imm.; procedure)
P-Plasminogen activator, tissue type; subst.c.(10 min after venistasis; imm.; procedure) = 210 pmol/l
 $M = 60,000$ g/mol
Not recommended term(s): Blood plasminogen activator; t-PA; Tissue plasminogen activator; Vascular plasminogen activator
Authority: ISTH/SSC93

Plasma–
Plasminogen activator, tissue type-Plasminogen activator inhibitor 1 complex;
substance concentration(imm.; procedure)
P-Plasminogen activator, tissue type-Plasminogen activator inhibitor 1 complex; subst.c.(imm.; procedure) = 100 pmol/l
 $M = 110,000$ g/mol
Not recommended term(s): t-PA-PAI 1-complex
Authority: Isth/SSC93

Plasma–
Plasminogen activator, tissue type-Plasminogen activator inhibitor 1 complex;
substance concentration
(stated time after venistasis; imm.; procedure)
P-Plasminogen activator, tissue type-Plasminogen activator inhibitor 1 complex; subst.c.(10 min after venistasis; imm.; procedure) = 250 pmol/l
 $M = 110,000$ g/mol
Not recommended term(s): t-PA-PAI 1-complex
Authority: Isth/SSC93

Plasma–
Plasminogen activator, urokinase type;
arbitrary substance concentration(procedure)
P-Plasminogen activator, urokinase type; arb. subst.c.(1st IS 87/594) = a int. unit/l
Calibrator: WHO 1st IS 87/594
Previous calibrator(s): WHO IRP 66/46
Not recommended term(s): UK; u-PA; Urokinase
Authority: Isth/SSC93

Plasma–
Platelet antibody;
arbitrary substance concentration(procedure)
P-Platelet antibody; arb. subst.c.(procedure) = a arb. unit/l
Not recommended term(s): Platelet specific alloantibody; Platelet autoantibody
Authority: Isth/SSC93

Plasma–
Platelet factor 4;
arbitrary substance concentration(procedure)
P-Platelet factor 4; arb. subst.c.(IS 83/505) = a int. unit/l
 $M = 7,800$ g/mol
Calibrator: WHO 1st IS 83/505
Not recommended term(s): PI-factor 4; Thrombocyte type heparin inactivator
Authority: Isth/SSC93

Plasma–
Platelet factor 4;
substance concentration
P-Platelet factor 4; subst.c.= a mol/l
 $M = 7,800$ g/mol
Not recommended term(s): PI-factor 4; Thrombocyte type heparin inactivator
Authority: Isth/SSC93

Blood –
Platelets;
number concentration
B-Platelets; num.c. = $250 \cdot 10^9/l$
Authority: Isth/SSC93

Plasma–
Prokallikrein;
arbitrary substance concentration(enz.; procedure)
P-Prokallikrein; arb. subst.c.(enz.; procedure) = a arb. unit/l
 $M = 86,000$ g/mol
Not recommended term(s): Fletcher factor; Prekallikrein; Prokininogenase; PK
Authority: Isth/SSC93

Plasma–
Prokallikrein;
substance concentration
P-Prokallikrein; subst.c.= 0.5 $\mu\text{mol/l}$
 $M = 86,000$ g/mol
Not recommended term(s): Fletcher factor; Prekallikrein; Prokininogenase; PK
Authority: Isth/SSC93

Plasma–
Proplasminogen activator, urokinase type;
substance concentration
P-Proplasminogen activator, urokinase type; subst.c.= 80 pmol/l
 $M = 54,000$ g/mol
Not recommended term(s): UK; u-PA; Urokinase
Authority: Isth/SSC93

Plasma–
6-keto-
Prostaglandin F1 α ;
substance concentration
P-6-keto-Prostaglandin F1 α ; subst.c.= a mol/l
 $M = 370.5$ g/mol
Authority: IFCC-IUPAC94

Plasma–
Protein C;
arbitrary substance concentration(coag.; procedure)
P-Protein C; arb. subst.c.(coag.; IS 86/622) = 1 k (int. unit)/l
 $M = 57,000$ g/mol
Calibrator: WHO 1st IS 86/622
Not recommended term(s): Autoprothrombin II-A
Authority: Isth/SSC93

Plasma–
Protein C;
arbitrary substance concentration(enz.; procedure)
P-Protein C; arb. subst.c.(enz.; IS 86/622) = 1 k (int. unit)/l
 $M = 57,000$ g/mol
Calibrator: WHO 1st IS 86/622
Not recommended term(s): Autoprothrombin II-A
Authority: Isth/SSC93

Plasma–
Protein C;
 substance concentration(imm.; procedure)
 P–Protein C; subst.c.(imm.; procedure) = 70 nmol/l
 M = 57,000 g/mol
 Not recommended term(s): Autoprothrombin II-A
 Authority: ISTH/SSC93

Plasma–
Protein C, activated inhibitor;
 substance concentration
 P–Protein C,a inhibitor; subst.c.= a pmol/l
 M = 57,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein C+acarboxy;
 substance concentration(imm.; procedure)
 P–Protein C+acarboxy; subst.c.(imm.; procedure) = 70 nmol/l
 M = 57,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S;
 arbitrary substance concentration(coag.; procedure)
 P–Protein S; arb. subst.c.(coag.; procedure) = a arb. unit/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S;
 arbitrary substance concentration(enz.; procedure)
 P–Protein S; arb. subst.c.(enz.; procedure) = a arb. unit/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S;
 substance concentration(imm.; procedure)
 P–Protein S; subst.c.(imm.; procedure) = 300 nmol/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S (free);
 substance concentration(coag.; procedure)
 P–Protein S (free); subst.c.(coag.; procedure) = 120 nmol/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S (free);
 substance concentration(imm.; procedure)
 P–Protein S (free); subst.c.(imm.; procedure) = 120 nmol/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Protein S+acarboxy;
 substance concentration(imm.; procedure)

P–Protein S+acarboxy; subst.c.(imm.; procedure) = 300 nmol/l
M = 75,000 g/mol
Authority: ISTH/SSC93

Plasma–
Protein S+acarboxy (free);
 substance concentration(imm.; procedure)
 P–Protein S+acarboxy(free); subst.c.(imm.; procedure) =
 120 nmol/l
 M = 75,000 g/mol
 Authority: ISTH/SSC93

Plasma–
Prothrombin;
 arbitrary substance concentration(coag.; procedure)
 P–Prothrombin; arb. subst.c.(coag.; procedure) = a arb. unit/l
 M = 68,700 g/mol
 Not recommended term(s): Coagulation factor II
 Authority: ISTH/SSC93

Plasma–
Prothrombin;
 substance concentration(imm.; procedure)
 P–Prothrombin; subst.c.(imm.; procedure) = 1.5 µmol/l
 M = 68,700 g/mol
 Not recommended term(s): Coagulation factor II
 Authority: ISTH/SSC 93

Plasma–
Prothrombin+acarboxy;
 substance concentration(imm.; procedure)
 P–Prothrombin+acarboxy; subst.c.(imm.; procedure) =
 1.5 µmol/l
 M = 68,700 g/mol
 Authority: ISTH/SSC93

Plasma–
Streptokinase antibody;
 arbitrary substance concentration(procedure)
 P–Streptokinase antibody; arb. subst.c.(coagulum lysis) = a arb.
 unit/l
 Not recommended term(s): Streptokinase inhibitor; Streptokinase
 resistance
 Authority: ISTH/SSC93

Plasma–
Thrombin-Antithrombin complex;
 substance concentration
 P–Thrombin-Antithrombin complex; subst. c = 30 pmol/l
 M = 103,000 g/mol
 Not recommended term(s): Thrombin-Thrombin inhibitor I complex
 Authority: ISTH/SSC93

Plasma–
Thrombocyte antibody;
 arbitrary substance concentration(procedure)
 P–Thrombocyte antibody; arb. subst.c.(procedure) = a arb. unit/l
 Not recommended term(s): Thrombocyte specific alloantibody;
 Thrombocyte autoantibody
 Authority: ISTH/SSC93

Plasma–

Thrombocyte factor 4;

arbitrary substance concentration(procedure)

P–Thrombocyte factor 4; arb. subst.c.(IS 83/505) = a int. unit/l

$M = 7,800$ g/mol

Calibrator: WHO 1st IS 83/505

Not recommended term(s): PI-factor 4; Thrombocyte type heparin inactivator

Authority: ISTH/SSC93

Plasma–

Thrombocyte factor 4;

substance concentration

P–Thrombocyte factor 4; subst.c. = a mol/l

$M = 7,800$ g/mol

Not recommended term(s): PI-factor 4; Thrombocyte type heparin inactivator

Authority: ISTH/SSC93

Blood –

Thrombocytes;

number concentration

B–Thrombocytes; num.c. = $250 \times 10^9/l$

Authority: IFCC–IUPAC94

Plasma–

Thromboglobulin;

arbitrary substance concentration(procedure)

P–Thromboglobulin; arb. subst.c.(IS 83/501) = a int. unit/l

$M = 8800$ g/mol

Calibrator: WHO 1st IS 83/501

Authority: ISTH/SSC93

Plasma–

Thromboglobulin;

substance concentration

P–Thromboglobulin; subst.c. = a mol/l

$M = 8800$ g/mol

Authority: ISTH/SSC93

Plasma–

Thromboxane B2;

substance concentration

P–Thromboxane B2; subst.c. = a mol/l

$M = 370.5$ g/mol

Authority: ISTH/SSC93

Plasma–

Tissue-factor-pathway coagulation inhibitor;

arbitrary substance concentration(coag.; procedure)

P–Tissue-factor-pathway coagulation inhibitor; arb. subst. c. (coag.; procedure) = a arb. unit/l

$M = 40,000$ g/mol

Not recommended term(s): Extrinsic pathway inhibitor; EPI; Lipo-protein associated coagulation inhibitor; LACI

Authority: ISTH/SSC93

Plasma–

Tissue-factor-pathway coagulation inhibitor;

arbitrary substance concentration(enz.; procedure)

P–Tissue-factor-pathway coagulation inhibitor; arb. subst.c.(enz.; procedure) = a arb. unit/l

$M = 40,000$ g/mol

Not recommended term(s): Extrinsic pathway inhibitor; EPI; Lipo-protein associated coagulation inhibitor; LACI

Authority: ISTH/SSC93

Plasma–

Tissue-factor-pathway coagulation inhibitor;

arbitrary substance concentration(imm.; procedure)

P–Tissue-factor-pathway coagulation inhibitor; arb. subst.c.(imm.; procedure) = a arb. unit/l

$M = 40,000$ g/mol

Not recommended term(s): Extrinsic pathway inhibitor; EPI; Lipo-protein associated coagulation inhibitor; LACI

Authority: ISTH/SSC93

Plasma–

Tissue-factor-pathway coagulation inhibitor;

relative substance concentration(imm.; actual/norm)

P–Tissue-factor-pathway coagulation inhibitor; rel. subst.c.(imm.; actual/norm) = 1.2

$M = 40,000$ g/mol

Not recommended term(s): Extrinsic pathway inhibitor; EPI; Lipo-protein associated coagulation inhibitor; LACI

Authority: ISTH/SSC93

Plasma–

Tissue-factor-pathway coagulation inhibitor;

substance concentration(imm.; procedure)

P–Tissue-factor-pathway coagulation inhibitor; subst.c.(imm.; procedure) = 2.5 nmol/l

$M = 40,000$ g/mol

Not recommended term(s): Extrinsic pathway inhibitor; EPI; Lipo-protein associated coagulation inhibitor; LACI

Authority: ISTH/SSC93

Plasma–

Tissue thromboplastin factor;

substance concentration(imm.; procedure)

P–Tissue thromboplastin factor; subst.c.(imm.; procedure) = a mol/l

$M = 47,000$ g/mol

Not recommended term(s): Coagulation factor III; TF; Thromboplastin

Authority: ISTH/SSC93

Plasma–

Vitronectin;

substance concentration

P–Vitronectin; subst.c. = 5 $\mu\text{mol/l}$

$M = 75,000$ g/mol

Not recommended term(s): Epibolin; S-protein; Serum-spreading factor

Authority: ISTH/SSC93

Plasma–

Von Willebrand factor;

arbitrary substance concentration(adhesion; procedure)

P–Von Willebrand factor; arb. subst.c.(adhesion; procedure) =

a arb. unit/l

Not recommended term(s): Von Willebrand factor activity; ristocetin cofactor activity

Authority: ISTH/SSC93

Note: Component subunits in series of multimers

Plasma–

Von Willebrand factor;

arbitrary substance concentration(imm.; procedure)

P–Von Willebrand factor; arb. subst.c.(imm.; IS 91/666) = 1 k(int. unit)/l

Calibrator: WHO 3rd IS 91/666

Previous calibrator(s): WHO 2nd IS 87/718

Not recommended term(s): AHF-like antigen; Factor VIIR:ag; Factor VIII-related antigen

Authority: ISTH/SSC93

Note: Component subunits in series of multimers

Plasma–

Von Willebrand factor;

arbitrary substance concentration(ristocetin cofactor activity; procedure)

P–Von Willebrand factor; arb. subst.c.(rist. cofact. act.; IS 91/666) = a int. unit/l

Calibrator: WHO 3rd IS 91/666

Previous calibrator(s): WHO 2nd IS 87/718

Not recommended term(s): Von Willebrand factor activity

Authority: ISTH/SSC93

Plasma–

Von Willebrand factor antibody;

arbitrary substance concentration(ristocetin cofactor activity inhibition; procedure)

P–Von Willebrand factor antibody; arb. subst.c.(rist. cofact. act. inh.; procedure) = a arb. unit/l

Authority: ISTH/SSC93

Plasma–

Von Willebrand factor multimers;

arbitrary substance concentration(imm. blott.; procedure)

P–Von Willebrand factor multimers; arb. subst.c.(imm. blott.; procedure; 0 1 2 3 arb. unit) = 2 arb. unit

Authority: ISTH/SSC93

Plasma–

Von Willebrand factor multimers(large);

arbitrary substance concentration(imm. blott.; procedure)

P–Von Willebrand factor multimers (large); arb. subst.c.(imm. blott.; procedure; 0 1 2 3 arb. unit) = 2 arb. unit

authority: ISTH/SSC93

Plasma–

Von Willebrand factor multimers(small);

arbitrary substance concentration(imm. blott.; procedure)

P–Von Willebrand factor multimers (small); arb. subst.c.(imm. blott.; procedure; 0 1 2 3 arb. unit) = 2 arb. unit

Authority: ISTH/SSC93

INDEX

α_1 -cysteine proteinase inhibitor

Kininogen (120,000)

α_1 -thiol proteinase inhibitor

Kininogen (120,000)

α_2 -Antiplasmin

Plasmin inhibitor

α_2 -AP

Plasmin inhibitor

Activated partial thromboplastin time

Coagulation, surface-induced

AHF

Coagulation factor VIII

AHF-like antigen

Von Willebrand factor

AHG

Coagulation factor VIII

Antihemophilic factor

Coagulation factor VIII

Antihemophilic factor B

Coagulation factor IX

Antihemophilic factor C

Coagulation factor XI

Antihemophilic globulin

Coagulation factor VIII

Antithrombin III

Antithrombin

aPTT; APTT

Coagulation, surface-induced

Autoprothrombin II-A

Protein C

Autoprothrombin III

Coagulation factor X

Autorosette inhibition factor

Histidine-rich glycoprotein

β -2-glycoprotein 1

Apolipoprotein H

Bleeding time

Capillary bleeding

Blood plasminogen activator

Plasminogen activator, tissue type

C1 esterase inhibitor

Complement C1 esterase inhibitor

C1 INA

Complement C1 esterase inhibitor

C1 Inactivator

Complement C1 esterase inhibitor

C1 INH

Complement C1 esterase inhibitor

C1 inhibitor

Complement C1 esterase inhibitor

C1/A

Complement C1 esterase inhibitor

Christmas factor
 Coagulation factor IX
 Circulating anticoagulant
 Coagulation factor VIII antibody
 Coagulation factor I
 Fibrinogen
 Coagulation factor II
 Prothrombin
 Coagulation factor III
 Tissue thromboplastin factor
 Coagulation factor IV
 Calcium ion(free)
 Coagulation factor IX inhibitor
 Coagulation factor IX antibody
 Coagulation factor V inhibitor
 Coagulation factor V antibody
 Coagulation factor VII inhibitor
 Coagulation factor VII antibody
 Coagulation factor VIII inhibitor
 Coagulation factor VIII antibody
 Coagulation factor XI inhibitor
 Coagulation factor XI antibody
 Coagulation factor XII inhibitor
 Coagulation factor XII antibody
 Coagulation factor XIII inhibitor
 Coagulation factor XIII antibody
 Coagulation inhibiting antibody
 Lupus anticoagulant
 Coagulation time
 Coagulation
 Dermatan sulphate cofactor
 Heparin cofactor II
 Endothelial cell type PAI
 Plasminogen activator inhibitor 1
 EPI
 Tissue-factor-pathway coagulation inhibitor
 Epibolin
 Vitronectin
 Euglobulin clot lysis time
 Coagulum lysis
 Extrinsic pathway inhibitor
 Tissue-factor-pathway coagulation inhibitor
 Factor IX:Ag
 Coagulation factor IX
 Factor VIII clotting activity
 Coagulation factor VIII
 Factor VIII-related antigen
 Von Willebrand factor
 Factor VIII:C:Ag
 Coagulation factor VIII
 Factor VIII:R:Ag
 Von Willebrand factor
 Fast acting PAI
 Plasminogen activator inhibitor 1
 FDP
 Fibrin + fibrinogen fragments
 Fibrin stabilizing factor
 Coagulation factor XIII
 Fibrinase Laki-Lorand factor
 Coagulation factor XIII
 Fibrinogen degradation products
 Fibrin + fibrinogen fragments
 Fibrinogen related antigens
 Fibrin + fibrinogen fragments
 Fibrinogen split products
 Fibrin + fibrinogen fragments
 Fibrinoligase
 Coagulation factor XIII
 Fitzgerald factor
 Kininogen (120,000)
 Flaujeac factor
 Kininogen (120,000)
 Fletcher factor
 Prokallikrein
 Hageman factor
 Coagulation factor XII
 Heparin cofactor I
 Antithrombin
 HK
 Kininogen (120,000)
 HMrK
 Kininogen (120,000)
 HMW kininogen
 Kininogen (120,000)
 HRG
 Histidine-rich glycoprotein
 HRGP
 Histidine-rich glycoprotein
 LACI
 Tissue-factor-pathway coagulation inhibitor
 Lipoprotein-associated coagulation inhibitor
 Tissue-factor-pathway coagulation inhibitor
 LK
 Kininogen (68,000)
 Lupus inhibitor
 Lupus anticoagulant
 P & P
 Coagulation, tissue factor-induced
 PA-inhibitor 2
 Plasminogen activator inhibitor 2
 PA-inhibitor I
 Plasminogen activator inhibitor 1
 PAI 1
 Plasminogen activator inhibitor 1
 PAI 2
 Plasminogen activator inhibitor 2
 PK
 Prokallikrein
 PI-factor 4
 Platelet factor 4 and Thrombocyte factor 4
 Placental PADII
 Plasminogen activator inhibitor 2
 Plasma thromboplastin antecedent
 Coagulation factor XI
 Plasma thromboplastin component
 Coagulation factor IX
 Plasma transamidase
 Coagulation factor XIII
 Plasma transglutaminase
 Coagulation factor XIII
 Plasmin- α 2-Antiplasmin complex
 Plasmin-plasmin inhibitor complex
 Platelet autoantibody
 Platelet antibody
 Platelet PAI
 Plasminogen activator inhibitor 1
 Platelet specific alloantibody
 Platelet antibody
 PLG
 Plasminogen
 Plgn
 Plasminogen

PP-time
 Coagulation, tissue factor-induced
 Prekallikrein
 Prokallikrein
 Primary fibrinolysis inhibitor
 Plasmin inhibitor
 Primary plasmin inhibitor
 Plasmin inhibitor
 Proaccelerin
 Coagulation factor V
 Proaccelerin accelerator globulin
 Coagulation factor V
 Proconvertin
 Coagulation factor VII
 Profibrinolysin
 Plasminogen
 Prokininogenase
 Prokallikrein
 Prothrombin complex
 Coagulation, tissue factor-induced
 Prothrombin time
 Coagulation, tissue factor-induced
 Prothrombin time ratio
 Coagulation, tissue factor-induced
 Prothrombin (factors II + VII + X)
 Coagulation, tissue factor-induced
 Prothrombin + proconvertin
 Coagulation, tissue factor-induced
 Prothrombokinase
 Coagulation factor X
 Protransglutaminase
 Coagulation factor XIII
 PTA
 Coagulation factor XI
 PTC
 Coagulation factor IX
 Recalcification time
 Coagulation, calcium ion-induced
 Ristocetin cofactor activity
 Von Willebrand factor
 S-protein
 Vitronectin
 Serum prothrombin conversion accelerator
 Coagulation factor VII
 Serum-spreading factor
 Vitronectin
 SPCA
 Coagulation factor VII
 Streptokinase inhibitor
 Streptokinase antibody
 Streptokinase resistance
 Streptokinase antibody
 Stuart-Prower factor
 Coagulation factor X
 t-PA
 Plasminogen activator, tissue type
 t-PA inhibitor
 Plasminogen activator inhibitor 1
 t-PA-PAI 1-complex
 Plasminogen activator, tissue type-Plasminogen activator inhib.
 TF
 Tissue thromboplastin factor
 The labile factor
 Coagulation factor V
 Thrombin inhibitor I
 Antithrombin
 Thrombin inhibitor II
 Heparin cofactor II
 Thrombin time
 Coagulation, thrombin-induced
 Thrombin-Thrombin inhibitor I complex
 Thrombin-Antithrombin complex
 Thrombocyte autoantibody
 Thrombocyte antibody
 Thrombocyte cofactor II
 Coagulation factor IX
 Thrombocyte specific alloantibody
 Thrombocyte antibody
 Thrombocyte type heparin inactivator
 Platelet factor 4 and Thrombocyte factor 4
 Thromboplastin
 Tissue thromboplastin factor
 Thromboplastin time
 Coagulation, tissue factor-induced
 Tissue plasminogen activator
 Plasminogen activator, tissue type
 u-PA
 Plasminogen activator, urokinase type and
 Proplasminogen activator, urokinase type
 u-PA-inhibitor
 Plasminogen activator inhibitor 2
 UK
 Plasminogen activator, urokinase type and
 Proplasminogen activator, urokinase type
 Urokinase
 Plasminogen activator, urokinase type and
 Proplasminogen activator, urokinase type
 Vascular plasminogen activator
 Plasminogen activator, tissue type
 VIII:Ag
 Coagulation factor VIII
 VIII:C
 Coagulation factor VIII
 Von Willebrand factor activity
 Von Willebrand factor
 Williams factor
 Kininogen (120,000)